Erytech Pharma SA (ERYP) stock prices were up by a massive 60.15% some time after market trading commenced on July 30th, 2021, bringing the price per share up to USD$6.58 early on in the trading day.
ERYP Stock’s Market Scope
Asparaginase has been a core part of ERYP stock’s ALL treatment for several years but has been associated with hypersensitivity that adversely affects treatment. This hypersensitivity affects up to 30% of all patients undergoing the treatment, making it a serious problem. The discontinuation of asparaginase therapy has been linked to inferior event-free survival, emphasizing the need for other asparaginase based treatment options.
Results of Eryaspase Trial
December 2020 saw ERYP stock report positive results from its Phase 2 trial, designed to evaluate the safety and enzyme activity of eryaspase. The treatment targeted primarily pediatric ALL patients who developed hypersensitivity reactions to pegylated asparaginase. Results from the study were presented by the Nordic Society of Pediatric Hematology and Oncology at the 2020 American Society of Hematology annual meeting.
Details of the Results
The data presented showed that the combination of eryaspase and chemotherapy provided a sustained asparaginase enzyme activity level when administered every two weeks. The treatment was generally well tolerated with few hypersensitivity reactions. ERYP stock recently confirmed its plans to submit a Biologics License Application (BLA) for eryaspase in this indication. The submission is expected for the fourth quarter of 2021, contingent on the successful completion of remaining steps.
ERYP Stock Granted Fast Track Designation
The United States Food and Drug Administration’s Fast Track program is designed to facilitate the accelerated development and review of new drugs, either alone or in conjunction with other drugs. This leeway is granted to drugs that can be used to treat serious or life threatening conditions that have a demonstrated potential for an unmet medical need that needs to be addressed. April 2020 had seen ERYA stock’s eryaspase being granted Fast Track designation, which facilitated the development of a second-line treatment of patients that suffer from metastatic pancreatic cancer. A Phase 3 trial in the indication completed enrollment of patients in January 2021, with results expected for Q4 2021.
Future Outlook for ERYP Stock
Armed with the concurrent development of its promising clinical trials, ERYP is poised to allocate resources to capitalize on its Fast Track Designations. The company is keen to facilitate the pushed up expected timeline for commercialization of its products. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.
